Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7657590 | 0.84 | TDP1 (0.58) | TDP1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2135355 | 0.82 | ALDH1A1 (0.56) | TDP1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2264423 | 0.82 | TDP1 (0.49) | TDP1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL18380090 | 0.81 | TDP1 (0.51) | TDP1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15156444 | 0.81 | TDP1 (0.45) | TDP1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL10713235 | 0.80 | TDP1 (0.58) | TDP1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2542848 | 0.78 | HSD17B10 (0.46) | TDP1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL12364210 | 0.78 | TDP1 (0.51) | TDP1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5951526 | 0.78 | TDP1 (0.51) | TDP1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL653911 | 0.77 | TDP1 (0.81) | TDP1MEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348857-B1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-8410284-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-04-02 | — | — | US | disclosed |
| US-8394969-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | TDP1 3641/4885MEN1 3565/4885KMT2A 2171/4885 |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | TDP1 3641/4885MEN1 3565/4885KMT2A 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.